GLP-1 Receptor Agonist for Reduction of Myocardial Injury After Non-cardiac Surgery

Launched by THE UNIVERSITY OF HONG KONG · Mar 19, 2024

Keywords

ClinConnect Summary

This clinical trial is studying whether a medication called Dulaglutide (also known as Trulicity) can help reduce heart injury in patients who are having non-cardiac surgery, which is surgery that doesn’t involve the heart. The trial involves 372 participants who will be randomly assigned to either receive a single dose of this medication a week or two before their surgery or continue with standard care. The researchers will closely monitor the patients' heart health and overall safety to see if this treatment can make a positive difference.

To participate in this study, you need to be at least 45 years old and scheduled for a specific type of surgery under general anesthesia, with an expected hospital stay of at least one night. However, there are some health conditions that would prevent you from joining, such as a recent history of heart problems, certain types of cancer, or severe kidney disease. If you’re eligible and choose to participate, you’ll have regular health assessments before and after the surgery to ensure your safety and to gather important information about the effectiveness of the medication. This trial is currently recruiting participants, and everyone is welcome regardless of gender.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 45 years
• • Planned elective intermediate to high risk non-cardiac surgery under general anesthesia
• • Anticipated to remain hospitalized for at least one night after surgery
• • Voluntarily agrees to participate by providing written informed consent
• Exclusion Criteria:
• • History of symptomatic hypoglycemia within 1 month of recruitment
• • History of pancreatitis
• • Diabetic retinopathy
• • Personal or family history of medullary thyroid carcinoma (MTC)
• • Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• • Acute coronary syndrome, decompensated heart failure, cardiogenic shock, or myocarditis within 1 month of recruitment
• • Stroke or transient ischemic attack within 1 month of recruitment
• • Known severe liver disease (Child-Pugh B or C)
• • Stage 5 chronic kidney disease (estimated glomerular filtration rate (eGFR) by Modified Diet in Renal Disease (MDRD) equation \< 15 mL/min)
• • Recent use of GLP-1 RA within 1 month of recruitment
• • Known allergy or hypersensitivity to GLP-1 RA
• • Women of childbearing age who are not taking effective contraception, or who are pregnant or breast-feeding
• • Use of Dipeptidyl peptidase-4 inhibitor(DPP4i)